Systemic sclerosis;Systemische sklerose/sklerodermie

Medizinische Monatsschrift fur Pharmazeuten

Volumn 31, Issue 5, 2008, Pages 162-170

  Tamborrini, Giorgio ^a   Distler, Meike ^a   Distler, Oliver ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; ANTIBIOTIC AGENT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROMYCIN; FLUOXETINE; ILOPROST; LOSARTAN; METHOTREXATE; METOCLOPRAMIDE; OCTREOTIDE; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROTON PUMP INHIBITOR; SILDENAFIL; SITAXSENTAN; UNIPROST; IMMUNOSUPPRESSIVE AGENT;

ACUTE KIDNEY FAILURE; BACTERIAL OVERGROWTH; CLINICAL FEATURE; FIBROSING ALVEOLITIS; FINGERTIP ULCER; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL MOTILITY DISORDER; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; REVIEW; SKIN FIBROSIS; SKIN ULCER; SYSTEMIC SCLEROSIS; THERAPY EFFECT; TREATMENT RESPONSE; EVIDENCE BASED MEDICINE; FIBROSIS; HUMAN; KIDNEY DISEASE; PATHOLOGY;

EVIDENCE-BASED MEDICINE; FIBROSIS; GASTROESOPHAGEAL REFLUX; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC;

EID: 46649111354     PISSN: 03429601     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Abraham D, Distler O. How does endothelial cell injury start? The role of endothelin in systemic sclerosis. Arthritis Res Ther 2007:9(Suppl 2):S2.
2. Allanore Y, Kahan A. Treatment of systemic sclerosis. Joint Bone Spine 2006;73:363-8.
3. Baroni SS, Santillo M, Bevilacqua F, Luchetti M, et al. Stimulatory auto-antibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006;354:2667-76.
4. Charles C, Clements P, Furst DE. Systemic sclerosis: hypothesis-driven treatment strategies. Lancet 2006;367:1683-91.
5. Clements PJ, Roth MD, et al. Scleroderma lung study: differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. Ann Rheum Dis 2007;66:1641-7.
6. Denton CP, Black CM. Scleroderma and related disorders: therapeutic aspects. Baillière's Clin Rheumatol 2000;14:17-35.
7. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007;117:557-67.
8. Distler JH, Gay S, Distler O. Angiogenesis and vasculogenesis in systemic sclerosis. Rheumatology (Oxford) 2006;45(Suppl 3):iii26-7.
9. Distler JH, Hoeper MM, Distler O. Diagnosis of pulmonary arterial hypertension in a patient with systemic sclerosis. Nat Clin Pract Rheumatol 2008;4:160-4.
10. Distler M, Distler J, Ciurea A, Kyburz D, et al. Evidence-based therapy of Raynaud's syndrome. Z Rheumatol 2006;65:285-9.
11. Distler O, Pignone A. Pulmonary arterial hypertension and rheumatic diseases - from diagnosis to treatment. Rheumatology (Oxford) 2006;45(Suppl 4):iv22-5.
12. Galie N, Ghofrani HA, Torbicki A, Barst RJ, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57.
13. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005;353:1412-3.
14. Gliddon AE, Dore CJ, Black CM, et al. Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon. Arthritis Rheum 2007; 56:3837-46.
15. Hoyles RK, Ellis RW, Wellsbury J, Lees B, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006;54:3962-70.
16. Huber LC, Fischler M, Distler O, Gay S, et al. Aktuelle Therapieansätze zur Behandlung der pulmonalen arteriellen Hypertonie (PAH). Arzneimitteltherapie 2007;25:364-73.
17. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-36.
18. Koch AE, Distler O. Vasculopathy and disordered angiogenesis in connective tissue disease. Arthritis Res Ther 2007;9(Suppl 2):S3.
19. Korn HJ, Mayes M, Matucci M, et al. Digital ulcers in systemic sclerosis. Arthritis Rheum 2004;50:3985-93.
20. Olschewski H, Simonneau G, Galie N, Higenbottam T, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-9.
21. Pickenpack A, Glück T, Distler O, v Landenberg P, et al. Notfälle in der Rheumatologie: Häufig verkannte Komplikationen systemischer Erkrankungen und ihrer Therapie. Teil 1: Vaskuläre und renale Komplikationen. Intensivmedizin und Notfallmedizin 2001;38:200-10.
22. Pope JE, Bellamy N, Seibold JR, Baron M, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001;44:1351-8.
23. Rubin LJ, Badesch DB, Barst RJ, Galie N, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
24. Tashkin DP, Elashoff R, Clements PJ, Goldin J, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-66.
25. Van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996;35:364-72.
26. Van Laar JM, Tyndall A. Adult stem cells in the treatment of autoimmune diseases. Rheumatology (Oxford) 2006;45:1187-93.
27. Wigley FM. Clinical practice. Raynaud's phenomenon. N Engl J Med 2002;347:1001-8.
28. Zulian F, Vallongo C, et al. Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum 2005;52:2873-81.
29. Abou-Raya A, Abou-Raya S, Helmii M. Statins as immunomodulators in systemic sclerosis. Ann N Y Acad Sci 2007;1110:670-80.
30. Kuwana M, Kaburaki J, Okazaki Y, Yasuoka H, et al. Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis. Arthritis Rheum 2006;54:1946-51.